Loading…

In Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence

Although immune checkpoint inhibitors have emerged as a breakthrough in cancer therapy, a monotherapy approach is not sufficient. Here, we report an immune checkpoint inhibitor-modified nanoparticle for an in situ-assembled tumor vaccine that can activate immune systems in the tumor microenvironment...

Full description

Saved in:
Bibliographic Details
Published in:ACS nano 2019-07, Vol.13 (7), p.7442-7462
Main Authors: Le, Quoc-Viet, Suh, Juhan, Choi, Jin Joo, Park, Gyu Thae, Lee, Jung Weon, Shim, Gayong, Oh, Yu-Kyoung
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a399t-fd52f7617dc09fde53f10ff3b8d1d71fa3c8701c4cbfb22982a71d244bc31e323
cites cdi_FETCH-LOGICAL-a399t-fd52f7617dc09fde53f10ff3b8d1d71fa3c8701c4cbfb22982a71d244bc31e323
container_end_page 7462
container_issue 7
container_start_page 7442
container_title ACS nano
container_volume 13
creator Le, Quoc-Viet
Suh, Juhan
Choi, Jin Joo
Park, Gyu Thae
Lee, Jung Weon
Shim, Gayong
Oh, Yu-Kyoung
description Although immune checkpoint inhibitors have emerged as a breakthrough in cancer therapy, a monotherapy approach is not sufficient. Here, we report an immune checkpoint inhibitor-modified nanoparticle for an in situ-assembled tumor vaccine that can activate immune systems in the tumor microenvironment and prevent the long-term recurrence of tumors. Adjuvant-loaded nanoparticles were prepared by entrapping imiquimod (IQ) in photoresponsive polydopamine nanoparticles (IQ/PNs). The surfaces of IQ/PNs were then modified with anti-PDL1 antibody (PDL1Ab-IQ/PNs) for in situ assembly with inactivated tumor cells and immune checkpoint blocking of PDL1 (programmed cell death 1 ligand 1). The presence of anti-PDL1 antibodies on IQ/PNs increased the binding of nanoparticles to CT26 cancer cells overexpressing PDL1. Subsequent near-infrared (NIR) irradiation induced a greater photothermal anticancer effect against cells treated with PDL1Ab-IQ/PNs than cells treated with plain PNs or unmodified IQ/PNs. To mimic the tumor microenvironment, we cocultured bone marrow-derived dendritic cells with CT26 cells treated with various nanoparticle formulations and NIR irradiated. This coculture study revealed that NIR-inactivated, PDL1Ab-IQ/PN-bound CT26 cells induced maturation of dendritic cells to the greatest extent. Following a single intravenous administration of different nanoparticle formulations in CT26 tumor-bearing mice, PDL1Ab-IQ/PNs showed greater tumor tissue accumulation than unmodified nanoparticles. Subsequent NIR irradiation of mice treated with PDL1Ab-IQ/PNs resulted in tumor ablation. In addition to primary tumor ablation, PDL1Ab-IQ/PNs completely prevented the growth of a secondarily challenged CT26 tumor at a distant site, producing 100% survival for up to 150 days. A long-term protection study revealed that treatment with PDL1Ab-IQ/PNs followed by NIR irradiation inhibited the growth of distant, secondarily challenged CT26 tumors 150 days after the first tumor inoculation. Moreover, increased infiltration of T cells was observed in tumor tissues treated with PDL1Ab-IQ/PNs and NIR-irradiated, and T cells isolated from splenocytes of mice in which tumor recurrence was prevented showed active killing of CT26 cells. These results suggest that PDL1Ab-IQ/PNs in conjunction with NIR irradiation induce a potent, in situ-assembled, all-in-one tumor vaccine with adjuvant-containing nanoparticle-bound, inactivated tumor cells. Such in situ nanoadjuvant-assembled tumor va
doi_str_mv 10.1021/acsnano.9b02071
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2248373331</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2248373331</sourcerecordid><originalsourceid>FETCH-LOGICAL-a399t-fd52f7617dc09fde53f10ff3b8d1d71fa3c8701c4cbfb22982a71d244bc31e323</originalsourceid><addsrcrecordid>eNp1kM9LwzAYhoMobk7P3qRHQbrlS9qmPY7hj8HQoVO8lTT5MjrWdCbtwP_eyupunr738LwPfC8h10DHQBlMpPJW2nqcFZRRASdkCBlPQpomn6fHHMOAXHi_oTQWqUjOyYADpDSJ2JAs5zZ4K5s2eO40Um_avbRNOPUeq2KLOli1Ve2CD6lUaTEwXV463KNtSrsOFrVdhyt0VfCKqnUOrcJLcmbk1uNVf0fk_eF-NXsKFy-P89l0EUqeZU1odMyMSEBoRTOjMeYGqDG8SDVoAUZylQoKKlKFKRjLUiYFaBZFheKAnPERuT14d67-atE3eVV6hduttFi3PmcsSrngnEOHTg6ocrX3Dk2-c2Ul3XcONP-dMe9nzPsZu8ZNL2-LCvWR_9utA-4OQNfMN3XrbPfrv7oftFx-Sw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2248373331</pqid></control><display><type>article</type><title>In Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Le, Quoc-Viet ; Suh, Juhan ; Choi, Jin Joo ; Park, Gyu Thae ; Lee, Jung Weon ; Shim, Gayong ; Oh, Yu-Kyoung</creator><creatorcontrib>Le, Quoc-Viet ; Suh, Juhan ; Choi, Jin Joo ; Park, Gyu Thae ; Lee, Jung Weon ; Shim, Gayong ; Oh, Yu-Kyoung</creatorcontrib><description>Although immune checkpoint inhibitors have emerged as a breakthrough in cancer therapy, a monotherapy approach is not sufficient. Here, we report an immune checkpoint inhibitor-modified nanoparticle for an in situ-assembled tumor vaccine that can activate immune systems in the tumor microenvironment and prevent the long-term recurrence of tumors. Adjuvant-loaded nanoparticles were prepared by entrapping imiquimod (IQ) in photoresponsive polydopamine nanoparticles (IQ/PNs). The surfaces of IQ/PNs were then modified with anti-PDL1 antibody (PDL1Ab-IQ/PNs) for in situ assembly with inactivated tumor cells and immune checkpoint blocking of PDL1 (programmed cell death 1 ligand 1). The presence of anti-PDL1 antibodies on IQ/PNs increased the binding of nanoparticles to CT26 cancer cells overexpressing PDL1. Subsequent near-infrared (NIR) irradiation induced a greater photothermal anticancer effect against cells treated with PDL1Ab-IQ/PNs than cells treated with plain PNs or unmodified IQ/PNs. To mimic the tumor microenvironment, we cocultured bone marrow-derived dendritic cells with CT26 cells treated with various nanoparticle formulations and NIR irradiated. This coculture study revealed that NIR-inactivated, PDL1Ab-IQ/PN-bound CT26 cells induced maturation of dendritic cells to the greatest extent. Following a single intravenous administration of different nanoparticle formulations in CT26 tumor-bearing mice, PDL1Ab-IQ/PNs showed greater tumor tissue accumulation than unmodified nanoparticles. Subsequent NIR irradiation of mice treated with PDL1Ab-IQ/PNs resulted in tumor ablation. In addition to primary tumor ablation, PDL1Ab-IQ/PNs completely prevented the growth of a secondarily challenged CT26 tumor at a distant site, producing 100% survival for up to 150 days. A long-term protection study revealed that treatment with PDL1Ab-IQ/PNs followed by NIR irradiation inhibited the growth of distant, secondarily challenged CT26 tumors 150 days after the first tumor inoculation. Moreover, increased infiltration of T cells was observed in tumor tissues treated with PDL1Ab-IQ/PNs and NIR-irradiated, and T cells isolated from splenocytes of mice in which tumor recurrence was prevented showed active killing of CT26 cells. These results suggest that PDL1Ab-IQ/PNs in conjunction with NIR irradiation induce a potent, in situ-assembled, all-in-one tumor vaccine with adjuvant-containing nanoparticle-bound, inactivated tumor cells. Such in situ nanoadjuvant-assembled tumor vaccines can be further developed for long-term prevention of tumor recurrence without the need for chemotherapy.</description><identifier>ISSN: 1936-0851</identifier><identifier>EISSN: 1936-086X</identifier><identifier>DOI: 10.1021/acsnano.9b02071</identifier><identifier>PMID: 31180642</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><ispartof>ACS nano, 2019-07, Vol.13 (7), p.7442-7462</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a399t-fd52f7617dc09fde53f10ff3b8d1d71fa3c8701c4cbfb22982a71d244bc31e323</citedby><cites>FETCH-LOGICAL-a399t-fd52f7617dc09fde53f10ff3b8d1d71fa3c8701c4cbfb22982a71d244bc31e323</cites><orcidid>0000-0002-0969-3339</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31180642$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Le, Quoc-Viet</creatorcontrib><creatorcontrib>Suh, Juhan</creatorcontrib><creatorcontrib>Choi, Jin Joo</creatorcontrib><creatorcontrib>Park, Gyu Thae</creatorcontrib><creatorcontrib>Lee, Jung Weon</creatorcontrib><creatorcontrib>Shim, Gayong</creatorcontrib><creatorcontrib>Oh, Yu-Kyoung</creatorcontrib><title>In Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence</title><title>ACS nano</title><addtitle>ACS Nano</addtitle><description>Although immune checkpoint inhibitors have emerged as a breakthrough in cancer therapy, a monotherapy approach is not sufficient. Here, we report an immune checkpoint inhibitor-modified nanoparticle for an in situ-assembled tumor vaccine that can activate immune systems in the tumor microenvironment and prevent the long-term recurrence of tumors. Adjuvant-loaded nanoparticles were prepared by entrapping imiquimod (IQ) in photoresponsive polydopamine nanoparticles (IQ/PNs). The surfaces of IQ/PNs were then modified with anti-PDL1 antibody (PDL1Ab-IQ/PNs) for in situ assembly with inactivated tumor cells and immune checkpoint blocking of PDL1 (programmed cell death 1 ligand 1). The presence of anti-PDL1 antibodies on IQ/PNs increased the binding of nanoparticles to CT26 cancer cells overexpressing PDL1. Subsequent near-infrared (NIR) irradiation induced a greater photothermal anticancer effect against cells treated with PDL1Ab-IQ/PNs than cells treated with plain PNs or unmodified IQ/PNs. To mimic the tumor microenvironment, we cocultured bone marrow-derived dendritic cells with CT26 cells treated with various nanoparticle formulations and NIR irradiated. This coculture study revealed that NIR-inactivated, PDL1Ab-IQ/PN-bound CT26 cells induced maturation of dendritic cells to the greatest extent. Following a single intravenous administration of different nanoparticle formulations in CT26 tumor-bearing mice, PDL1Ab-IQ/PNs showed greater tumor tissue accumulation than unmodified nanoparticles. Subsequent NIR irradiation of mice treated with PDL1Ab-IQ/PNs resulted in tumor ablation. In addition to primary tumor ablation, PDL1Ab-IQ/PNs completely prevented the growth of a secondarily challenged CT26 tumor at a distant site, producing 100% survival for up to 150 days. A long-term protection study revealed that treatment with PDL1Ab-IQ/PNs followed by NIR irradiation inhibited the growth of distant, secondarily challenged CT26 tumors 150 days after the first tumor inoculation. Moreover, increased infiltration of T cells was observed in tumor tissues treated with PDL1Ab-IQ/PNs and NIR-irradiated, and T cells isolated from splenocytes of mice in which tumor recurrence was prevented showed active killing of CT26 cells. These results suggest that PDL1Ab-IQ/PNs in conjunction with NIR irradiation induce a potent, in situ-assembled, all-in-one tumor vaccine with adjuvant-containing nanoparticle-bound, inactivated tumor cells. Such in situ nanoadjuvant-assembled tumor vaccines can be further developed for long-term prevention of tumor recurrence without the need for chemotherapy.</description><issn>1936-0851</issn><issn>1936-086X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kM9LwzAYhoMobk7P3qRHQbrlS9qmPY7hj8HQoVO8lTT5MjrWdCbtwP_eyupunr738LwPfC8h10DHQBlMpPJW2nqcFZRRASdkCBlPQpomn6fHHMOAXHi_oTQWqUjOyYADpDSJ2JAs5zZ4K5s2eO40Um_avbRNOPUeq2KLOli1Ve2CD6lUaTEwXV463KNtSrsOFrVdhyt0VfCKqnUOrcJLcmbk1uNVf0fk_eF-NXsKFy-P89l0EUqeZU1odMyMSEBoRTOjMeYGqDG8SDVoAUZylQoKKlKFKRjLUiYFaBZFheKAnPERuT14d67-atE3eVV6hduttFi3PmcsSrngnEOHTg6ocrX3Dk2-c2Ul3XcONP-dMe9nzPsZu8ZNL2-LCvWR_9utA-4OQNfMN3XrbPfrv7oftFx-Sw</recordid><startdate>20190723</startdate><enddate>20190723</enddate><creator>Le, Quoc-Viet</creator><creator>Suh, Juhan</creator><creator>Choi, Jin Joo</creator><creator>Park, Gyu Thae</creator><creator>Lee, Jung Weon</creator><creator>Shim, Gayong</creator><creator>Oh, Yu-Kyoung</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0969-3339</orcidid></search><sort><creationdate>20190723</creationdate><title>In Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence</title><author>Le, Quoc-Viet ; Suh, Juhan ; Choi, Jin Joo ; Park, Gyu Thae ; Lee, Jung Weon ; Shim, Gayong ; Oh, Yu-Kyoung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a399t-fd52f7617dc09fde53f10ff3b8d1d71fa3c8701c4cbfb22982a71d244bc31e323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Le, Quoc-Viet</creatorcontrib><creatorcontrib>Suh, Juhan</creatorcontrib><creatorcontrib>Choi, Jin Joo</creatorcontrib><creatorcontrib>Park, Gyu Thae</creatorcontrib><creatorcontrib>Lee, Jung Weon</creatorcontrib><creatorcontrib>Shim, Gayong</creatorcontrib><creatorcontrib>Oh, Yu-Kyoung</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>ACS nano</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Le, Quoc-Viet</au><au>Suh, Juhan</au><au>Choi, Jin Joo</au><au>Park, Gyu Thae</au><au>Lee, Jung Weon</au><au>Shim, Gayong</au><au>Oh, Yu-Kyoung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence</atitle><jtitle>ACS nano</jtitle><addtitle>ACS Nano</addtitle><date>2019-07-23</date><risdate>2019</risdate><volume>13</volume><issue>7</issue><spage>7442</spage><epage>7462</epage><pages>7442-7462</pages><issn>1936-0851</issn><eissn>1936-086X</eissn><abstract>Although immune checkpoint inhibitors have emerged as a breakthrough in cancer therapy, a monotherapy approach is not sufficient. Here, we report an immune checkpoint inhibitor-modified nanoparticle for an in situ-assembled tumor vaccine that can activate immune systems in the tumor microenvironment and prevent the long-term recurrence of tumors. Adjuvant-loaded nanoparticles were prepared by entrapping imiquimod (IQ) in photoresponsive polydopamine nanoparticles (IQ/PNs). The surfaces of IQ/PNs were then modified with anti-PDL1 antibody (PDL1Ab-IQ/PNs) for in situ assembly with inactivated tumor cells and immune checkpoint blocking of PDL1 (programmed cell death 1 ligand 1). The presence of anti-PDL1 antibodies on IQ/PNs increased the binding of nanoparticles to CT26 cancer cells overexpressing PDL1. Subsequent near-infrared (NIR) irradiation induced a greater photothermal anticancer effect against cells treated with PDL1Ab-IQ/PNs than cells treated with plain PNs or unmodified IQ/PNs. To mimic the tumor microenvironment, we cocultured bone marrow-derived dendritic cells with CT26 cells treated with various nanoparticle formulations and NIR irradiated. This coculture study revealed that NIR-inactivated, PDL1Ab-IQ/PN-bound CT26 cells induced maturation of dendritic cells to the greatest extent. Following a single intravenous administration of different nanoparticle formulations in CT26 tumor-bearing mice, PDL1Ab-IQ/PNs showed greater tumor tissue accumulation than unmodified nanoparticles. Subsequent NIR irradiation of mice treated with PDL1Ab-IQ/PNs resulted in tumor ablation. In addition to primary tumor ablation, PDL1Ab-IQ/PNs completely prevented the growth of a secondarily challenged CT26 tumor at a distant site, producing 100% survival for up to 150 days. A long-term protection study revealed that treatment with PDL1Ab-IQ/PNs followed by NIR irradiation inhibited the growth of distant, secondarily challenged CT26 tumors 150 days after the first tumor inoculation. Moreover, increased infiltration of T cells was observed in tumor tissues treated with PDL1Ab-IQ/PNs and NIR-irradiated, and T cells isolated from splenocytes of mice in which tumor recurrence was prevented showed active killing of CT26 cells. These results suggest that PDL1Ab-IQ/PNs in conjunction with NIR irradiation induce a potent, in situ-assembled, all-in-one tumor vaccine with adjuvant-containing nanoparticle-bound, inactivated tumor cells. Such in situ nanoadjuvant-assembled tumor vaccines can be further developed for long-term prevention of tumor recurrence without the need for chemotherapy.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>31180642</pmid><doi>10.1021/acsnano.9b02071</doi><tpages>21</tpages><orcidid>https://orcid.org/0000-0002-0969-3339</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1936-0851
ispartof ACS nano, 2019-07, Vol.13 (7), p.7442-7462
issn 1936-0851
1936-086X
language eng
recordid cdi_proquest_miscellaneous_2248373331
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
title In Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A32%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Situ%20Nanoadjuvant-Assembled%20Tumor%20Vaccine%20for%20Preventing%20Long-Term%20Recurrence&rft.jtitle=ACS%20nano&rft.au=Le,%20Quoc-Viet&rft.date=2019-07-23&rft.volume=13&rft.issue=7&rft.spage=7442&rft.epage=7462&rft.pages=7442-7462&rft.issn=1936-0851&rft.eissn=1936-086X&rft_id=info:doi/10.1021/acsnano.9b02071&rft_dat=%3Cproquest_cross%3E2248373331%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a399t-fd52f7617dc09fde53f10ff3b8d1d71fa3c8701c4cbfb22982a71d244bc31e323%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2248373331&rft_id=info:pmid/31180642&rfr_iscdi=true